Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients
Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Asahi Ito [verfasserIn] Yui Suzuki [verfasserIn] Ayako Masaki [verfasserIn] Shinichiro Yoshida [verfasserIn] Hitoshi Suzushima [verfasserIn] Shigeki Takemoto [verfasserIn] Atae Utsunomiya [verfasserIn] Toshihiko Ishii [verfasserIn] Masanori Hiura [verfasserIn] Takeshi Takahashi [verfasserIn] Satoshi Yurimoto [verfasserIn] Hiroshi Inagaki [verfasserIn] Akimichi Morita [verfasserIn] Shinsuke Iida [verfasserIn] Takashi Ishida [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Journal of Cutaneous Immunology and Allergy - Wiley, 2018, 2(2019), 4, Seite 102-107 |
|---|---|
| Übergeordnetes Werk: |
volume:2 ; year:2019 ; number:4 ; pages:102-107 |
| Links: |
|---|
| DOI / URN: |
10.1002/cia2.12070 |
|---|
| Katalog-ID: |
DOAJ015078191 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ015078191 | ||
| 003 | DE-627 | ||
| 005 | 20240413131206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cia2.12070 |2 doi | |
| 035 | |a (DE-627)DOAJ015078191 | ||
| 035 | |a (DE-599)DOAJ1b8fc13cc8ab42f4ad0fd3df134da49b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RL1-803 | |
| 050 | 0 | |a RC581-607 | |
| 100 | 0 | |a Asahi Ito |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in some patients, including rare cases of Stevens‐Johnson syndrome. Hence, we aimed to elucidate immunological primary reactions in skins of mogamulizumab by quantitatively comparing any patterns of other skin disorders. Methods We quantitatively analyzed Foxp3+, CD8+, CD4+, granzyme B+, CD56+, and macrophage‐derived chemokine‐positive cells, and compared the results with trends observed in other inflammatory skin disorders such as psoriasis vulgaris, atopic dermatitis, and lichen planus. The analysis was separately performed in dermis, basement membrane, or epidermis of skins. Results Foxp3+/CD8+ cell ratio in dermis and basement membrane of mogamulizumab‐emergent skin disorders was significantly lower compared with those of the other skin disorders. In inflammatory skins, the more the number of CD8+ cells were infiltrated, the more the number of Foxp3+ cells were prone to be infiltrated, but not in mogamulizumab‐emergent skin disorders. No significant difference between all of the other skin disorders was observed in other immunological markers. Conclusion The low Foxp3+/CD8+ cell ratio of skins is the underlying reason for mogamulizumab‐emergent skin disorders. | ||
| 650 | 4 | |a CD8 | |
| 650 | 4 | |a FoxP3 | |
| 650 | 4 | |a mogamulizumab | |
| 653 | 0 | |a Dermatology | |
| 653 | 0 | |a Immunologic diseases. Allergy | |
| 700 | 0 | |a Yui Suzuki |e verfasserin |4 aut | |
| 700 | 0 | |a Ayako Masaki |e verfasserin |4 aut | |
| 700 | 0 | |a Shinichiro Yoshida |e verfasserin |4 aut | |
| 700 | 0 | |a Hitoshi Suzushima |e verfasserin |4 aut | |
| 700 | 0 | |a Shigeki Takemoto |e verfasserin |4 aut | |
| 700 | 0 | |a Atae Utsunomiya |e verfasserin |4 aut | |
| 700 | 0 | |a Toshihiko Ishii |e verfasserin |4 aut | |
| 700 | 0 | |a Masanori Hiura |e verfasserin |4 aut | |
| 700 | 0 | |a Takeshi Takahashi |e verfasserin |4 aut | |
| 700 | 0 | |a Satoshi Yurimoto |e verfasserin |4 aut | |
| 700 | 0 | |a Hiroshi Inagaki |e verfasserin |4 aut | |
| 700 | 0 | |a Akimichi Morita |e verfasserin |4 aut | |
| 700 | 0 | |a Shinsuke Iida |e verfasserin |4 aut | |
| 700 | 0 | |a Takashi Ishida |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Cutaneous Immunology and Allergy |d Wiley, 2018 |g 2(2019), 4, Seite 102-107 |w (DE-627)1022185543 |w (DE-600)2929465-4 |x 25744593 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2019 |g number:4 |g pages:102-107 |
| 856 | 4 | 0 | |u https://doi.org/10.1002/cia2.12070 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/1b8fc13cc8ab42f4ad0fd3df134da49b |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1002/cia2.12070 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2574-4593 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2056 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2019 |e 4 |h 102-107 | ||
| author_variant |
a i ai y s ys a m am s y sy h s hs s t st a u au t i ti m h mh t t tt s y sy h i hi a m am s i si t i ti |
|---|---|
| matchkey_str |
article:25744593:2019----::uniaieymuooiacaatrztoomgmlzmbkn |
| hierarchy_sort_str |
2019 |
| callnumber-subject-code |
RL |
| publishDate |
2019 |
| allfields |
10.1002/cia2.12070 doi (DE-627)DOAJ015078191 (DE-599)DOAJ1b8fc13cc8ab42f4ad0fd3df134da49b DE-627 ger DE-627 rakwb eng RL1-803 RC581-607 Asahi Ito verfasserin aut Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in some patients, including rare cases of Stevens‐Johnson syndrome. Hence, we aimed to elucidate immunological primary reactions in skins of mogamulizumab by quantitatively comparing any patterns of other skin disorders. Methods We quantitatively analyzed Foxp3+, CD8+, CD4+, granzyme B+, CD56+, and macrophage‐derived chemokine‐positive cells, and compared the results with trends observed in other inflammatory skin disorders such as psoriasis vulgaris, atopic dermatitis, and lichen planus. The analysis was separately performed in dermis, basement membrane, or epidermis of skins. Results Foxp3+/CD8+ cell ratio in dermis and basement membrane of mogamulizumab‐emergent skin disorders was significantly lower compared with those of the other skin disorders. In inflammatory skins, the more the number of CD8+ cells were infiltrated, the more the number of Foxp3+ cells were prone to be infiltrated, but not in mogamulizumab‐emergent skin disorders. No significant difference between all of the other skin disorders was observed in other immunological markers. Conclusion The low Foxp3+/CD8+ cell ratio of skins is the underlying reason for mogamulizumab‐emergent skin disorders. CD8 FoxP3 mogamulizumab Dermatology Immunologic diseases. Allergy Yui Suzuki verfasserin aut Ayako Masaki verfasserin aut Shinichiro Yoshida verfasserin aut Hitoshi Suzushima verfasserin aut Shigeki Takemoto verfasserin aut Atae Utsunomiya verfasserin aut Toshihiko Ishii verfasserin aut Masanori Hiura verfasserin aut Takeshi Takahashi verfasserin aut Satoshi Yurimoto verfasserin aut Hiroshi Inagaki verfasserin aut Akimichi Morita verfasserin aut Shinsuke Iida verfasserin aut Takashi Ishida verfasserin aut In Journal of Cutaneous Immunology and Allergy Wiley, 2018 2(2019), 4, Seite 102-107 (DE-627)1022185543 (DE-600)2929465-4 25744593 nnns volume:2 year:2019 number:4 pages:102-107 https://doi.org/10.1002/cia2.12070 kostenfrei https://doaj.org/article/1b8fc13cc8ab42f4ad0fd3df134da49b kostenfrei https://doi.org/10.1002/cia2.12070 kostenfrei https://doaj.org/toc/2574-4593 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2019 4 102-107 |
| spelling |
10.1002/cia2.12070 doi (DE-627)DOAJ015078191 (DE-599)DOAJ1b8fc13cc8ab42f4ad0fd3df134da49b DE-627 ger DE-627 rakwb eng RL1-803 RC581-607 Asahi Ito verfasserin aut Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in some patients, including rare cases of Stevens‐Johnson syndrome. Hence, we aimed to elucidate immunological primary reactions in skins of mogamulizumab by quantitatively comparing any patterns of other skin disorders. Methods We quantitatively analyzed Foxp3+, CD8+, CD4+, granzyme B+, CD56+, and macrophage‐derived chemokine‐positive cells, and compared the results with trends observed in other inflammatory skin disorders such as psoriasis vulgaris, atopic dermatitis, and lichen planus. The analysis was separately performed in dermis, basement membrane, or epidermis of skins. Results Foxp3+/CD8+ cell ratio in dermis and basement membrane of mogamulizumab‐emergent skin disorders was significantly lower compared with those of the other skin disorders. In inflammatory skins, the more the number of CD8+ cells were infiltrated, the more the number of Foxp3+ cells were prone to be infiltrated, but not in mogamulizumab‐emergent skin disorders. No significant difference between all of the other skin disorders was observed in other immunological markers. Conclusion The low Foxp3+/CD8+ cell ratio of skins is the underlying reason for mogamulizumab‐emergent skin disorders. CD8 FoxP3 mogamulizumab Dermatology Immunologic diseases. Allergy Yui Suzuki verfasserin aut Ayako Masaki verfasserin aut Shinichiro Yoshida verfasserin aut Hitoshi Suzushima verfasserin aut Shigeki Takemoto verfasserin aut Atae Utsunomiya verfasserin aut Toshihiko Ishii verfasserin aut Masanori Hiura verfasserin aut Takeshi Takahashi verfasserin aut Satoshi Yurimoto verfasserin aut Hiroshi Inagaki verfasserin aut Akimichi Morita verfasserin aut Shinsuke Iida verfasserin aut Takashi Ishida verfasserin aut In Journal of Cutaneous Immunology and Allergy Wiley, 2018 2(2019), 4, Seite 102-107 (DE-627)1022185543 (DE-600)2929465-4 25744593 nnns volume:2 year:2019 number:4 pages:102-107 https://doi.org/10.1002/cia2.12070 kostenfrei https://doaj.org/article/1b8fc13cc8ab42f4ad0fd3df134da49b kostenfrei https://doi.org/10.1002/cia2.12070 kostenfrei https://doaj.org/toc/2574-4593 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2019 4 102-107 |
| allfields_unstemmed |
10.1002/cia2.12070 doi (DE-627)DOAJ015078191 (DE-599)DOAJ1b8fc13cc8ab42f4ad0fd3df134da49b DE-627 ger DE-627 rakwb eng RL1-803 RC581-607 Asahi Ito verfasserin aut Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in some patients, including rare cases of Stevens‐Johnson syndrome. Hence, we aimed to elucidate immunological primary reactions in skins of mogamulizumab by quantitatively comparing any patterns of other skin disorders. Methods We quantitatively analyzed Foxp3+, CD8+, CD4+, granzyme B+, CD56+, and macrophage‐derived chemokine‐positive cells, and compared the results with trends observed in other inflammatory skin disorders such as psoriasis vulgaris, atopic dermatitis, and lichen planus. The analysis was separately performed in dermis, basement membrane, or epidermis of skins. Results Foxp3+/CD8+ cell ratio in dermis and basement membrane of mogamulizumab‐emergent skin disorders was significantly lower compared with those of the other skin disorders. In inflammatory skins, the more the number of CD8+ cells were infiltrated, the more the number of Foxp3+ cells were prone to be infiltrated, but not in mogamulizumab‐emergent skin disorders. No significant difference between all of the other skin disorders was observed in other immunological markers. Conclusion The low Foxp3+/CD8+ cell ratio of skins is the underlying reason for mogamulizumab‐emergent skin disorders. CD8 FoxP3 mogamulizumab Dermatology Immunologic diseases. Allergy Yui Suzuki verfasserin aut Ayako Masaki verfasserin aut Shinichiro Yoshida verfasserin aut Hitoshi Suzushima verfasserin aut Shigeki Takemoto verfasserin aut Atae Utsunomiya verfasserin aut Toshihiko Ishii verfasserin aut Masanori Hiura verfasserin aut Takeshi Takahashi verfasserin aut Satoshi Yurimoto verfasserin aut Hiroshi Inagaki verfasserin aut Akimichi Morita verfasserin aut Shinsuke Iida verfasserin aut Takashi Ishida verfasserin aut In Journal of Cutaneous Immunology and Allergy Wiley, 2018 2(2019), 4, Seite 102-107 (DE-627)1022185543 (DE-600)2929465-4 25744593 nnns volume:2 year:2019 number:4 pages:102-107 https://doi.org/10.1002/cia2.12070 kostenfrei https://doaj.org/article/1b8fc13cc8ab42f4ad0fd3df134da49b kostenfrei https://doi.org/10.1002/cia2.12070 kostenfrei https://doaj.org/toc/2574-4593 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2019 4 102-107 |
| allfieldsGer |
10.1002/cia2.12070 doi (DE-627)DOAJ015078191 (DE-599)DOAJ1b8fc13cc8ab42f4ad0fd3df134da49b DE-627 ger DE-627 rakwb eng RL1-803 RC581-607 Asahi Ito verfasserin aut Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in some patients, including rare cases of Stevens‐Johnson syndrome. Hence, we aimed to elucidate immunological primary reactions in skins of mogamulizumab by quantitatively comparing any patterns of other skin disorders. Methods We quantitatively analyzed Foxp3+, CD8+, CD4+, granzyme B+, CD56+, and macrophage‐derived chemokine‐positive cells, and compared the results with trends observed in other inflammatory skin disorders such as psoriasis vulgaris, atopic dermatitis, and lichen planus. The analysis was separately performed in dermis, basement membrane, or epidermis of skins. Results Foxp3+/CD8+ cell ratio in dermis and basement membrane of mogamulizumab‐emergent skin disorders was significantly lower compared with those of the other skin disorders. In inflammatory skins, the more the number of CD8+ cells were infiltrated, the more the number of Foxp3+ cells were prone to be infiltrated, but not in mogamulizumab‐emergent skin disorders. No significant difference between all of the other skin disorders was observed in other immunological markers. Conclusion The low Foxp3+/CD8+ cell ratio of skins is the underlying reason for mogamulizumab‐emergent skin disorders. CD8 FoxP3 mogamulizumab Dermatology Immunologic diseases. Allergy Yui Suzuki verfasserin aut Ayako Masaki verfasserin aut Shinichiro Yoshida verfasserin aut Hitoshi Suzushima verfasserin aut Shigeki Takemoto verfasserin aut Atae Utsunomiya verfasserin aut Toshihiko Ishii verfasserin aut Masanori Hiura verfasserin aut Takeshi Takahashi verfasserin aut Satoshi Yurimoto verfasserin aut Hiroshi Inagaki verfasserin aut Akimichi Morita verfasserin aut Shinsuke Iida verfasserin aut Takashi Ishida verfasserin aut In Journal of Cutaneous Immunology and Allergy Wiley, 2018 2(2019), 4, Seite 102-107 (DE-627)1022185543 (DE-600)2929465-4 25744593 nnns volume:2 year:2019 number:4 pages:102-107 https://doi.org/10.1002/cia2.12070 kostenfrei https://doaj.org/article/1b8fc13cc8ab42f4ad0fd3df134da49b kostenfrei https://doi.org/10.1002/cia2.12070 kostenfrei https://doaj.org/toc/2574-4593 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2019 4 102-107 |
| allfieldsSound |
10.1002/cia2.12070 doi (DE-627)DOAJ015078191 (DE-599)DOAJ1b8fc13cc8ab42f4ad0fd3df134da49b DE-627 ger DE-627 rakwb eng RL1-803 RC581-607 Asahi Ito verfasserin aut Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in some patients, including rare cases of Stevens‐Johnson syndrome. Hence, we aimed to elucidate immunological primary reactions in skins of mogamulizumab by quantitatively comparing any patterns of other skin disorders. Methods We quantitatively analyzed Foxp3+, CD8+, CD4+, granzyme B+, CD56+, and macrophage‐derived chemokine‐positive cells, and compared the results with trends observed in other inflammatory skin disorders such as psoriasis vulgaris, atopic dermatitis, and lichen planus. The analysis was separately performed in dermis, basement membrane, or epidermis of skins. Results Foxp3+/CD8+ cell ratio in dermis and basement membrane of mogamulizumab‐emergent skin disorders was significantly lower compared with those of the other skin disorders. In inflammatory skins, the more the number of CD8+ cells were infiltrated, the more the number of Foxp3+ cells were prone to be infiltrated, but not in mogamulizumab‐emergent skin disorders. No significant difference between all of the other skin disorders was observed in other immunological markers. Conclusion The low Foxp3+/CD8+ cell ratio of skins is the underlying reason for mogamulizumab‐emergent skin disorders. CD8 FoxP3 mogamulizumab Dermatology Immunologic diseases. Allergy Yui Suzuki verfasserin aut Ayako Masaki verfasserin aut Shinichiro Yoshida verfasserin aut Hitoshi Suzushima verfasserin aut Shigeki Takemoto verfasserin aut Atae Utsunomiya verfasserin aut Toshihiko Ishii verfasserin aut Masanori Hiura verfasserin aut Takeshi Takahashi verfasserin aut Satoshi Yurimoto verfasserin aut Hiroshi Inagaki verfasserin aut Akimichi Morita verfasserin aut Shinsuke Iida verfasserin aut Takashi Ishida verfasserin aut In Journal of Cutaneous Immunology and Allergy Wiley, 2018 2(2019), 4, Seite 102-107 (DE-627)1022185543 (DE-600)2929465-4 25744593 nnns volume:2 year:2019 number:4 pages:102-107 https://doi.org/10.1002/cia2.12070 kostenfrei https://doaj.org/article/1b8fc13cc8ab42f4ad0fd3df134da49b kostenfrei https://doi.org/10.1002/cia2.12070 kostenfrei https://doaj.org/toc/2574-4593 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2019 4 102-107 |
| language |
English |
| source |
In Journal of Cutaneous Immunology and Allergy 2(2019), 4, Seite 102-107 volume:2 year:2019 number:4 pages:102-107 |
| sourceStr |
In Journal of Cutaneous Immunology and Allergy 2(2019), 4, Seite 102-107 volume:2 year:2019 number:4 pages:102-107 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
CD8 FoxP3 mogamulizumab Dermatology Immunologic diseases. Allergy |
| isfreeaccess_bool |
true |
| container_title |
Journal of Cutaneous Immunology and Allergy |
| authorswithroles_txt_mv |
Asahi Ito @@aut@@ Yui Suzuki @@aut@@ Ayako Masaki @@aut@@ Shinichiro Yoshida @@aut@@ Hitoshi Suzushima @@aut@@ Shigeki Takemoto @@aut@@ Atae Utsunomiya @@aut@@ Toshihiko Ishii @@aut@@ Masanori Hiura @@aut@@ Takeshi Takahashi @@aut@@ Satoshi Yurimoto @@aut@@ Hiroshi Inagaki @@aut@@ Akimichi Morita @@aut@@ Shinsuke Iida @@aut@@ Takashi Ishida @@aut@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
1022185543 |
| id |
DOAJ015078191 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ015078191</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413131206.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/cia2.12070</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ015078191</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1b8fc13cc8ab42f4ad0fd3df134da49b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Asahi Ito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in some patients, including rare cases of Stevens‐Johnson syndrome. Hence, we aimed to elucidate immunological primary reactions in skins of mogamulizumab by quantitatively comparing any patterns of other skin disorders. Methods We quantitatively analyzed Foxp3+, CD8+, CD4+, granzyme B+, CD56+, and macrophage‐derived chemokine‐positive cells, and compared the results with trends observed in other inflammatory skin disorders such as psoriasis vulgaris, atopic dermatitis, and lichen planus. The analysis was separately performed in dermis, basement membrane, or epidermis of skins. Results Foxp3+/CD8+ cell ratio in dermis and basement membrane of mogamulizumab‐emergent skin disorders was significantly lower compared with those of the other skin disorders. In inflammatory skins, the more the number of CD8+ cells were infiltrated, the more the number of Foxp3+ cells were prone to be infiltrated, but not in mogamulizumab‐emergent skin disorders. No significant difference between all of the other skin disorders was observed in other immunological markers. Conclusion The low Foxp3+/CD8+ cell ratio of skins is the underlying reason for mogamulizumab‐emergent skin disorders.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CD8</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">FoxP3</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mogamulizumab</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yui Suzuki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ayako Masaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shinichiro Yoshida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hitoshi Suzushima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shigeki Takemoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Atae Utsunomiya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Toshihiko Ishii</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masanori Hiura</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takeshi Takahashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Satoshi Yurimoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Inagaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Akimichi Morita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shinsuke Iida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takashi Ishida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Cutaneous Immunology and Allergy</subfield><subfield code="d">Wiley, 2018</subfield><subfield code="g">2(2019), 4, Seite 102-107</subfield><subfield code="w">(DE-627)1022185543</subfield><subfield code="w">(DE-600)2929465-4</subfield><subfield code="x">25744593</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:102-107</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/cia2.12070</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1b8fc13cc8ab42f4ad0fd3df134da49b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/cia2.12070</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2574-4593</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2019</subfield><subfield code="e">4</subfield><subfield code="h">102-107</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Asahi Ito |
| spellingShingle |
Asahi Ito misc RL1-803 misc RC581-607 misc CD8 misc FoxP3 misc mogamulizumab misc Dermatology misc Immunologic diseases. Allergy Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients |
| authorStr |
Asahi Ito |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1022185543 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RL1-803 |
| illustrated |
Not Illustrated |
| issn |
25744593 |
| topic_title |
RL1-803 RC581-607 Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients CD8 FoxP3 mogamulizumab |
| topic |
misc RL1-803 misc RC581-607 misc CD8 misc FoxP3 misc mogamulizumab misc Dermatology misc Immunologic diseases. Allergy |
| topic_unstemmed |
misc RL1-803 misc RC581-607 misc CD8 misc FoxP3 misc mogamulizumab misc Dermatology misc Immunologic diseases. Allergy |
| topic_browse |
misc RL1-803 misc RC581-607 misc CD8 misc FoxP3 misc mogamulizumab misc Dermatology misc Immunologic diseases. Allergy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of Cutaneous Immunology and Allergy |
| hierarchy_parent_id |
1022185543 |
| hierarchy_top_title |
Journal of Cutaneous Immunology and Allergy |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1022185543 (DE-600)2929465-4 |
| title |
Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients |
| ctrlnum |
(DE-627)DOAJ015078191 (DE-599)DOAJ1b8fc13cc8ab42f4ad0fd3df134da49b |
| title_full |
Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients |
| author_sort |
Asahi Ito |
| journal |
Journal of Cutaneous Immunology and Allergy |
| journalStr |
Journal of Cutaneous Immunology and Allergy |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
txt |
| container_start_page |
102 |
| author_browse |
Asahi Ito Yui Suzuki Ayako Masaki Shinichiro Yoshida Hitoshi Suzushima Shigeki Takemoto Atae Utsunomiya Toshihiko Ishii Masanori Hiura Takeshi Takahashi Satoshi Yurimoto Hiroshi Inagaki Akimichi Morita Shinsuke Iida Takashi Ishida |
| container_volume |
2 |
| class |
RL1-803 RC581-607 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Asahi Ito |
| doi_str_mv |
10.1002/cia2.12070 |
| author2-role |
verfasserin |
| title_sort |
quantitatively immunological characterization of mogamulizumab skin disorders in atl patients |
| callnumber |
RL1-803 |
| title_auth |
Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients |
| abstract |
Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in some patients, including rare cases of Stevens‐Johnson syndrome. Hence, we aimed to elucidate immunological primary reactions in skins of mogamulizumab by quantitatively comparing any patterns of other skin disorders. Methods We quantitatively analyzed Foxp3+, CD8+, CD4+, granzyme B+, CD56+, and macrophage‐derived chemokine‐positive cells, and compared the results with trends observed in other inflammatory skin disorders such as psoriasis vulgaris, atopic dermatitis, and lichen planus. The analysis was separately performed in dermis, basement membrane, or epidermis of skins. Results Foxp3+/CD8+ cell ratio in dermis and basement membrane of mogamulizumab‐emergent skin disorders was significantly lower compared with those of the other skin disorders. In inflammatory skins, the more the number of CD8+ cells were infiltrated, the more the number of Foxp3+ cells were prone to be infiltrated, but not in mogamulizumab‐emergent skin disorders. No significant difference between all of the other skin disorders was observed in other immunological markers. Conclusion The low Foxp3+/CD8+ cell ratio of skins is the underlying reason for mogamulizumab‐emergent skin disorders. |
| abstractGer |
Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in some patients, including rare cases of Stevens‐Johnson syndrome. Hence, we aimed to elucidate immunological primary reactions in skins of mogamulizumab by quantitatively comparing any patterns of other skin disorders. Methods We quantitatively analyzed Foxp3+, CD8+, CD4+, granzyme B+, CD56+, and macrophage‐derived chemokine‐positive cells, and compared the results with trends observed in other inflammatory skin disorders such as psoriasis vulgaris, atopic dermatitis, and lichen planus. The analysis was separately performed in dermis, basement membrane, or epidermis of skins. Results Foxp3+/CD8+ cell ratio in dermis and basement membrane of mogamulizumab‐emergent skin disorders was significantly lower compared with those of the other skin disorders. In inflammatory skins, the more the number of CD8+ cells were infiltrated, the more the number of Foxp3+ cells were prone to be infiltrated, but not in mogamulizumab‐emergent skin disorders. No significant difference between all of the other skin disorders was observed in other immunological markers. Conclusion The low Foxp3+/CD8+ cell ratio of skins is the underlying reason for mogamulizumab‐emergent skin disorders. |
| abstract_unstemmed |
Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in some patients, including rare cases of Stevens‐Johnson syndrome. Hence, we aimed to elucidate immunological primary reactions in skins of mogamulizumab by quantitatively comparing any patterns of other skin disorders. Methods We quantitatively analyzed Foxp3+, CD8+, CD4+, granzyme B+, CD56+, and macrophage‐derived chemokine‐positive cells, and compared the results with trends observed in other inflammatory skin disorders such as psoriasis vulgaris, atopic dermatitis, and lichen planus. The analysis was separately performed in dermis, basement membrane, or epidermis of skins. Results Foxp3+/CD8+ cell ratio in dermis and basement membrane of mogamulizumab‐emergent skin disorders was significantly lower compared with those of the other skin disorders. In inflammatory skins, the more the number of CD8+ cells were infiltrated, the more the number of Foxp3+ cells were prone to be infiltrated, but not in mogamulizumab‐emergent skin disorders. No significant difference between all of the other skin disorders was observed in other immunological markers. Conclusion The low Foxp3+/CD8+ cell ratio of skins is the underlying reason for mogamulizumab‐emergent skin disorders. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
4 |
| title_short |
Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients |
| url |
https://doi.org/10.1002/cia2.12070 https://doaj.org/article/1b8fc13cc8ab42f4ad0fd3df134da49b https://doaj.org/toc/2574-4593 |
| remote_bool |
true |
| author2 |
Yui Suzuki Ayako Masaki Shinichiro Yoshida Hitoshi Suzushima Shigeki Takemoto Atae Utsunomiya Toshihiko Ishii Masanori Hiura Takeshi Takahashi Satoshi Yurimoto Hiroshi Inagaki Akimichi Morita Shinsuke Iida Takashi Ishida |
| author2Str |
Yui Suzuki Ayako Masaki Shinichiro Yoshida Hitoshi Suzushima Shigeki Takemoto Atae Utsunomiya Toshihiko Ishii Masanori Hiura Takeshi Takahashi Satoshi Yurimoto Hiroshi Inagaki Akimichi Morita Shinsuke Iida Takashi Ishida |
| ppnlink |
1022185543 |
| callnumber-subject |
RL - Dermatology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1002/cia2.12070 |
| callnumber-a |
RL1-803 |
| up_date |
2024-07-04T01:32:28.491Z |
| _version_ |
1803610225110941696 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ015078191</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413131206.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/cia2.12070</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ015078191</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1b8fc13cc8ab42f4ad0fd3df134da49b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Asahi Ito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in some patients, including rare cases of Stevens‐Johnson syndrome. Hence, we aimed to elucidate immunological primary reactions in skins of mogamulizumab by quantitatively comparing any patterns of other skin disorders. Methods We quantitatively analyzed Foxp3+, CD8+, CD4+, granzyme B+, CD56+, and macrophage‐derived chemokine‐positive cells, and compared the results with trends observed in other inflammatory skin disorders such as psoriasis vulgaris, atopic dermatitis, and lichen planus. The analysis was separately performed in dermis, basement membrane, or epidermis of skins. Results Foxp3+/CD8+ cell ratio in dermis and basement membrane of mogamulizumab‐emergent skin disorders was significantly lower compared with those of the other skin disorders. In inflammatory skins, the more the number of CD8+ cells were infiltrated, the more the number of Foxp3+ cells were prone to be infiltrated, but not in mogamulizumab‐emergent skin disorders. No significant difference between all of the other skin disorders was observed in other immunological markers. Conclusion The low Foxp3+/CD8+ cell ratio of skins is the underlying reason for mogamulizumab‐emergent skin disorders.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CD8</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">FoxP3</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mogamulizumab</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yui Suzuki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ayako Masaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shinichiro Yoshida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hitoshi Suzushima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shigeki Takemoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Atae Utsunomiya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Toshihiko Ishii</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masanori Hiura</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takeshi Takahashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Satoshi Yurimoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Inagaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Akimichi Morita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shinsuke Iida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takashi Ishida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Cutaneous Immunology and Allergy</subfield><subfield code="d">Wiley, 2018</subfield><subfield code="g">2(2019), 4, Seite 102-107</subfield><subfield code="w">(DE-627)1022185543</subfield><subfield code="w">(DE-600)2929465-4</subfield><subfield code="x">25744593</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:102-107</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/cia2.12070</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1b8fc13cc8ab42f4ad0fd3df134da49b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/cia2.12070</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2574-4593</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2019</subfield><subfield code="e">4</subfield><subfield code="h">102-107</subfield></datafield></record></collection>
|
| score |
7.3982677 |